within Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BX03_Piracetam;
model Piracetam 
   extends Pharmacolibrary.Drugs.ATC.N.N06BX03;

  annotation(Documentation(
    info ="<html><body><p>Piracetam is a nootropic agent, classified as a cyclic derivative of GABA, used to treat cognitive impairment and myoclonus. It is not FDA approved in the United States but is approved in some European and other countries for cognitive disorders, vertigo, and myoclonus.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers of both sexes after oral administration.</p><h4>References</h4><ol><li><p>Nash, EM, &amp; Sangha, KS (2001). Levetiracetam. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 58(13) 1195–1199. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/58.13.1195&quot;>10.1093/ajhp/58.13.1195</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11449876/&quot;>https://pubmed.ncbi.nlm.nih.gov/11449876</a></p></li><li><p>Carreno, M (2007). Levetiracetam. <i>Drugs of today (Barcelona, Spain : 1998)</i> 43(11) 769–794. DOI:<a href=&quot;https://doi.org/10.1358/dot.2007.43.11.1136902&quot;>10.1358/dot.2007.43.11.1136902</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18174964/&quot;>https://pubmed.ncbi.nlm.nih.gov/18174964</a></p></li><li><p>Radtke, RA (2001). Pharmacokinetics of levetiracetam. <i>Epilepsia</i> 42 Suppl 4 24–27. DOI:<a href=&quot;https://doi.org/10.1046/j.1528-1157.2001.0420s4024.x&quot;>10.1046/j.1528-1157.2001.0420s4024.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11564121/&quot;>https://pubmed.ncbi.nlm.nih.gov/11564121</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Piracetam;
